Reviewer's report

Title: Bronchodilatory effect of inhaled budesonide/formoterol and budesonide/salbutamol in acute asthma: A double-blind, randomized controlled trial.

Version: 3 Date: 16 December 2011

Reviewer: Edward Kerwin

Reviewer's report:

The authors are to be commended. The revised MS had addressed all of my prior comments, and I believe, made for a clear and strong MS on the possible use of BUD/FOR for acute treatment of asthma in children.

I recommend this MS for publication. All the revisions look appropriate and have improved the scientific content of the MS.

The revised MS appears acceptable for publication.

Edward M. Kerwin, MD

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

Dr. Kerwin has served on speakers panels or advisory boards for Astra Zeneca (MAP Pharma), Dey Laboratories, GlaxoSmithKline, Ironwood Pharmaceuticals, Merck (Schering Plough), Pfizer, Sanofi Aventis, Sunovion (Sepracor), Targacept, Teva Labs, and UCB Pharma.

He has conducted clinical research trials for fifty pharmaceutical companies.